| Code | CSB-RA004936MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BMS-986325, targeting CD40, a critical costimulatory molecule belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, B cells, and various non-immune cells, where it plays a pivotal role in regulating adaptive immunity and inflammatory responses. Upon binding with its ligand CD40L, CD40 initiates signaling cascades that promote T cell priming, B cell activation, antibody class switching, and cytokine production. Dysregulation of CD40 signaling has been implicated in autoimmune diseases, chronic inflammation, and cancer, making it a compelling therapeutic target for immune modulation.
BMS-986325 is an agonistic anti-CD40 antibody developed for cancer immunotherapy, designed to stimulate antitumor immune responses by activating dendritic cells and enhancing T cell-mediated immunity. This biosimilar provides researchers with a cost-effective tool for investigating CD40-mediated immune mechanisms, evaluating combination immunotherapy strategies, and exploring therapeutic interventions in oncology and autoimmune disease models. The antibody serves as a valuable reagent for preclinical studies examining CD40 pathway biology and immune checkpoint modulation.
There are currently no reviews for this product.